Pharmaceutical company Pfizer of New York City announced last month that it is exploring alternatives for its Medical Technology Group that could include the divestiture of the business as a whole or in parts. The division includes Pfizer's Schneider
Pharmaceutical company Pfizer of New York City announced last month that it is exploring alternatives for its Medical Technology Group that could include the divestiture of the business as a whole or in parts. The division includes Pfizer's Schneider Worldwide business, which develops interventional radiology and cardiology products such as angioplasty balloon catheters. Other units in the business include Howmedica, which develops orthopedic devices, and American Medical Systems, a developer of urological implants. Pfizer was active in the medical imaging market in the 1980s, marketing such technologies as CT and mammography, but eventually exited the business.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.